NEW YORK, Aug 14 – Incyte and the Guy's and St. Thomas' Hospital NHS Trust of London said Tuesday they had agreed to study osteoarthritis, a common arthritic condition that affects more than 21 million Americans.
Under the terms of the deal, Incyte will own the intellectual property stemming from the partnership.
Scientists at Guy's & St. Thomas' and at Incyte's laboratory in Cambridge, UK, said they would conduct a genetics study to elucidate the genetic component of osteoarthritis and to determine the effects particularly to the knee.
Incyte of Palo Alto, Calif., has already identified genes in its database that may have a role in the osteoarthritis, while the British researchers have been gathering data from patients with osteoarthritis of the knee for over 10 years.
"Osteoarthritis is an important priority area for the development of high value information to aid in the treatment and diagnosis of this debilitating disease," Roy Whitfield, Incyte’s CEO, said in a statement.
Incyte said it would use the information it gathers through the collaboration to develop new therapeutics and diagnostics for osteoarthritis, which predominantly affects the elderly.
Financial terms of the deal were not disclosed.